EVA HUBER ET AL: "Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity", CELL, CELL PRESS, US, vol. 148, no. 4, 2 December 2011 (2011-12-02), pages 727-738, XP028458988, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2011.12.030 [retrieved on 2012-01-12] (B1)

EVAM HUBER ET AL: "Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity", CELL, CELL PRESS, US, vol. 148, no. 4, 2 December 2011 (2011-12-02), pages 727-738, XP028458988, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2011.12.030 [retrieved on 2012-01-12] (B1)

M. SCREEN ET AL: "Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 51, 11 October 2010 (2010-10-11), pages 40125-40134, XP055099238, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.160606 (B1)

WOOIN LEE ET AL: "The Immunoproteasome: An Emerging Therapeutic Target", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 11, no. 23, 1 December 2011 (2011-12-01), pages 2923-2930, XP055129375, ISSN: 1568-0266, DOI: 10.2174/156802611798281348 (B1)

TONY MUCHAMUEL ET AL: "A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis", NATURE MEDICINE, vol. 15, no. 7, 1 July 2009 (2009-07-01), pages 781-787, XP055094218, ISSN: 1078-8956, DOI: 10.1038/nm.1978 (B1)

US-A1- 2007 105 786 (B1)

WO-A2-2007/149512 (B1)

S. E. VERBRUGGE ET AL: "Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 341, no. 1, 10 January 2012 (2012-01-10), pages 174-182, XP055129369, DOI: 10.1124/jpet.111.187542 (B1)